	US 12,257,276 B2
	Lactobacillus amylovorus LAM1345 isolate, composition including the same and use thereof
San-Land Young, Kaohsiung (TW); Hau-Yang Tsen, Taichung (TW); Chen-Ying Hung, Hsinchu County (TW); and Yu-Cheng Chiang, Taichung (TW)
Assigned to SYNBIO TECH INC., Kaohsiung (TW)
Appl. No. 17/606,977
Filed by SYNBIO TECH INC., Kaohsiung (TW)
PCT Filed Jun. 30, 2021, PCT No. PCT/CN2021/103607 § 371(c)(1), (2) Date Oct. 27, 2021, PCT Pub. No. WO2022/151669, PCT Pub. Date Jul. 21, 2022.
Claims priority of application No. 202110037395.2 (CN), filed on Jan. 12, 2021.
Prior Publication US 2022/0370522 A1, Nov. 24, 2022
Int. Cl. A61K 35/747 (2015.01); A61K 35/745 (2015.01); C12N 1/20 (2006.01); C12R 1/225 (2006.01)

CPC A61K 35/747 (2013.01) [A61K 35/745 (2013.01); C12N 1/205 (2021.05); C12R 2001/225 (2021.05)]

3 Claims

1. A method for treating a disease associated with at least an elevated one of trimethylamine (TMA) and trimethylamine-n-oxide (TMAO) levels, comprising:

administering, to a subject in need thereof, a pharmaceutical composition consisting of an isolated strain of Lactobacillus amylovorus LAM1345, which is deposited at Deutsche Sammlung von Mikroorganismen und Zellkulturen GmbH under an accession number DSM 33510; and a pharmaceutically acceptable carrier.